| Ident. | Authors (with country if any) | Title |
|---|
| 002728 |
Joost Besseling [Pays-Bas] ; Kwok Leung Ong [Australie] ; Roeland Huijgen [Pays-Bas] ; Kerry-Anne Rye [Australie] ; G Kees Hovingh [Pays-Bas] ; Barbara A. Hutten [Pays-Bas] ; Gilles Lambert [France] | The impact of LDLR function on fibroblast growth factor 21 levels. |
| 003866 |
Fatiha Tabet [Australie] ; Kasey C. Vickers [États-Unis] ; Luisa F. Cuesta Torres [Australie] ; Carrie B. Wiese [États-Unis] ; Bassem M. Shoucri [États-Unis] ; Gilles Lambert [France] ; Claire Catherinet [Australie] ; Leonel Prado-Lourenco [Australie] ; Michael G. Levin [États-Unis] ; Seth Thacker [États-Unis] ; Praveen Sethupathy [États-Unis] ; Philip J. Barter [Australie] ; Alan T. Remaley [États-Unis] ; Kerry-Anne Rye [Australie] | HDL-transferred microRNA-223 regulates ICAM-1 expression in endothelial cells |
| 003993 |
Gilles Lambert [Australie] ; Francine Petrides [Australie] ; Mathias Chatelais [France] ; Dirk J. Blom [Afrique du Sud] ; Benjamin Choque [Australie] ; Fatiha Tabet [Australie] ; Gida Wong [Australie] ; Kerry-Anne Rye [Australie] ; Amanda J. Hooper [Australie] ; John R. Burnett [Australie] ; Philip J. Barter [Australie] ; A David Marais [Afrique du Sud] | Elevated plasma PCSK9 level is equally detrimental for patients with nonfamilial hypercholesterolemia and heterozygous familial hypercholesterolemia, irrespective of low-density lipoprotein receptor defects. |
| 004187 |
Gilles Lambert [France, Australie] ; Francine Petrides [Australie] ; Mathias Chatelais [France] ; Dirk J. Blom [Afrique du Sud] ; Benjamin Choque [Australie] ; Fatiha Tabet [Australie] ; Gida Wong [Australie] ; Kerry-Anne Rye [Australie] ; Amanda J. Hooper [Australie] ; John R. Burnett [Australie] ; Philip J. Barter [Australie] ; A. David Marais [Afrique du Sud] | Elevated Plasma PCSK9 Level Is Equally Detrimental for Patients With Nonfamilial Hypercholesterolemia and Heterozygous Familial Hypercholesterolemia, Irrespective of Low-Density Lipoprotein Receptor Defects |
| 004D24 |
Arjan J. Kwakernaak [Pays-Bas] ; Gilles Lambert [Australie, France] ; Maartje C. J. Slagman [Pays-Bas] ; Femke Waanders [Pays-Bas] ; Gozewijn D. Laverman [Pays-Bas] ; Francine Petrides [Australie] ; Bert D. Dikkeschei [Pays-Bas] ; Gerjan Navis [Pays-Bas] ; Robin P. F. Dullaart [Pays-Bas] | Proprotein convertase subtilisin-kexin type 9 is elevated in proteinuric subjects: Relationship with lipoprotein response to antiproteinuric treatment |
| 005997 |
Roeland Huijgen [Pays-Bas] ; S. Matthijs Boekholdt [Pays-Bas] ; Benoit J. Arsenault [Pays-Bas] ; WEIHANG BAO [États-Unis] ; Jean-Michel Davaine [France] ; Fatiha Tabet [Australie] ; Francine Petrides [Australie] ; Kerry-Anne Rye [Australie] ; David A. Demicco [États-Unis] ; Philip J. Barter [Australie] ; John J. P. Kastelein [Pays-Bas] ; Gilles Lambert [France, Australie] | Plasma PCSK9 Levels and Clinical Outcomes in the TNT (Treating to New Targets) Trial: A Nested Case-Control Study |
| 006757 |
Paul J. W. H. Kappelle [Pays-Bas] ; Gilles Lambert [Australie, France] ; Björn Dahlb Ck [Suède, Pays-Bas] ; Lars Bo Nielsen [Danemark] ; Robin P. F. Dullaart [Suède, Pays-Bas] | Relationship of plasma apolipoprotein M with proprotein convertase subtilisin-kexin type 9 levels in non-diabetic subjects |
| 006823 |
Paul J. W. H. Kappelle [Pays-Bas] ; Gilles Lambert [Australie, France] ; Robin P. F. Dullaart [Pays-Bas] | Plasma proprotein convertase subtilisin-kexin type 9 does not change during 24 h insulin infusion in healthy subjects and type 2 diabetic patients |
| 006950 |
Fatiha Tabet [Australie] ; Gilles Lambert [Australie, France] ; Luisa F. Cuesta Torres [Australie] ; LIMING HOU [Australie] ; Irene Sotirchos [Australie] ; Rhian M. Touyz [Canada] ; Alicia J. Jenkins [Australie] ; Philip J. Barter [Australie] ; Kerry-Anne Rye [Australie] | Lipid-Free Apolipoprotein A-I and Discoidal Reconstituted High-Density Lipoproteins Differentially Inhibit Glucose-Induced Oxidative Stress in Human Macrophages |
| 006B18 |
Omar N. Akram [Australie] ; Christina Bursill [Australie] ; Reena Desai [Australie] ; Alison K. Heather [Australie] ; Rymantas Kazlauskas [Australie] ; David J. Handelsman [Australie] ; Gilles Lambert [Australie, France] | Evaluation of Androgenic Activity of Nutraceutical-Derived Steroids Using Mammalian and Yeast in Vitro Androgen Bioassays |
| 006F13 |
Estelle Nobécourt ; Fatiha Tabet ; Gilles Lambert [France] ; Rajesh Puranik [Australie] ; Shisan Bao [Australie] ; Ling Yan ; Michael J. Davies [Australie] ; Bronwyn E. Brown ; Alicia J. Jenkins [Australie] ; Gregory J. Dusting [Australie] ; David J. Bonnet ; Linda K. Curtiss ; Philip J. Barter [Australie] ; Kerry-Anne Rye [Australie] | Non-Enzymatic Glycation Impairs the Anti-Inflammatory Properties of Apolipoprotein A-I |
| 007484 |
Fatiha Tabet [Australie] ; Alan T. Remaley [États-Unis] ; Aude I. Segaliny [Australie] ; Jonathan Millet [Australie] ; LING YAN [Australie] ; Shirley Nakhla [Australie] ; Philip J. Barter [Australie] ; Kerry-Anne Rye [Australie] ; Gilles Lambert [France] | The 5A Apolipoprotein A-I Mimetic Peptide Displays Antiinflammatory and Antioxidant Properties In Vivo and In Vitro |
| 007684 |
Estelle Nobecourt [Australie] ; Fatiha Tabet [Australie] ; Gilles Lambert [Australie] ; Rajesh Puranik [Australie] ; SHISAN BAO [Australie] ; LING YAN [Australie] ; Michael J. Davies [Australie] ; Bronwyn E. Brown [Australie] ; Alicia J. Jenkins [France] ; Gregory J. Dusting [Australie] ; David J. Bonnet [Australie] ; Linda K. Curtiss [Australie] ; Philip J. Barter [Australie] ; Kerry-Anne Rye [États-Unis] | Nonenzymatic Glycation Impairs the Antiinflammatory Properties of Apolipoprotein A-I |
| 007B44 |
Kerry-Anne Rye [Australie] ; Christina A. Bursill [Australie] ; Gilles Lambert [Australie, France] ; Fatiha Tabet [Australie] ; Philip J. Barter [Australie] | The metabolism and anti-atherogenic properties of HDL |
| 007B54 |
Fatiha Tabet [Australie] ; Alan T. Remaley [États-Unis] ; Aude I. Segaliny [Australie] ; Jonathan Millet [Australie] ; Ling Yan [Australie] ; Shirley Nakhla [Australie] ; Philip J. Barter [Australie] ; Kerry-Anne Rye [Australie] ; Gilles Lambert [Australie, France] | The 5A apolipoprotein A-I mimetic peptide displays anti-inflammatory and antioxidant properties in vivo and in vitro |
| 008160 |
Dick C. Chan [Australie] ; Gilles Lambert [Australie, France] ; P. Hugh R. Barrett [Australie] ; Kerry-Anne Rye [Australie] ; Esther M. M. Ooi [Australie] ; Gerald F. Watts [Australie] | Plasma Proprotein Convertase Subtilisin/ Kexin Type 9: A Marker of LDL Apolipoprotein B-100 Catabolism? |
| 008206 |
Gilles Lambert [Australie, France] ; Francesca Charlton [Australie] ; Kerry-Anne Rye [Australie] ; Derek E. Piper [États-Unis] | Molecular basis of PCSK9 function |
| 008B26 |
Gilles Lambert [Australie, France] ; Nicolas Ancellin [France] ; Francesca Charlton [Australie] ; Daniel Comas [France] ; Julia Pilot [France] ; Anthony Keech [Australie] ; Sanjay Patel [Australie] ; David R. Sullivan [Australie] ; Jeffrey S. Cohn [Australie] ; Kerry-Anne Rye [Australie] ; Philip J. Batter [Australie] | Plasma PCSK9 Concentrations Correlate with LDL and Total Cholesterol in Diabetic Patients and Are Decreased by Fenofibrate Treatment |
| 008C80 |
Vivienne M. Homer [Nouvelle-Zélande] ; A. David Marais [Afrique du Sud] ; Francesca Charlton [Australie] ; Andrew D. Laurie [Nouvelle-Zélande] ; Nicola Hurndell [Nouvelle-Zélande] ; Russel Scott [Nouvelle-Zélande] ; Fabien Mangili [Australie] ; David R. Sullivan [Australie] ; Philip J. Barter [Australie] ; Kerry-Anne Rye [Australie] ; Peter M. George [Nouvelle-Zélande] ; Gilles Lambert [Australie, France] | Identification and characterization of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South Africa |
